Clinical Trial: The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
Brief Summary: Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.
Detailed Summary:
Sponsor: Samsung Medical Center
Current Primary Outcome: serum VEGF and Ang-2 level in lung inflammatory disease according to the presence of hemoptysis [ Time Frame: up to 7 days after enrollment ]
Original Primary Outcome: Same as current
Current Secondary Outcome: to investigate association between angiogenesis factors and other factors such as inflammatory biomarker and hypoxia. [ Time Frame: up to 7 days after enrollment ]
Original Secondary Outcome: Same as current
Information By: Samsung Medical Center
Dates:
Date Received: July 16, 2010
Date Started: June 2008
Date Completion:
Last Updated: July 20, 2011
Last Verified: July 2011